Abstract:Personalised cancer therapy aims to tailor treatment to individual tumour profiles, yet tumour heterogeneity and adaptive resistance continue to limit clinical efficacy. Drug combinations offer a strategy to overcome resistance by simultaneously targeting multiple pathways, but their rational design is constrained by the vast combinatorial search space and experimental cost. Here, we present an AI-guided, QSAR-driven iterative optimisation framework that integrates machine learning with automated experimental screening to enable closed-loop discovery of selective multi-drug therapies. Starting from an initial random screen, the system iteratively predicts, tests, and refines three-drug combinations targeting MCF7 breast cancer cells. Incorporation of non-tumorigenic MCF10A cells enables explicit optimisation of tumour-selective efficacy, prioritising regimens that maximise cancer cell killing while sparing healthy cells. Across successive iterations, the framework rapidly enriched for highly selective, high-efficacy combinations, while maintaining chemical and mechanistic diversity and avoiding convergence on a narrow solution space. By continuously learning from experimental feedback, the approach efficiently navigates millions of combinations to identify a small set of validated, tumour-selective regimens. These results establish a scalable proof-of-concept for AI-driven, closed-loop optimisation of higher-order drug combinations, demonstrating how iterative integration of computation and experimentation can enable adaptive and potentially personalised therapeutic design in precision oncology.
From: Abbi Abdel-Rehim [view email]
[v1]
Thu, 4 Jun 2026 15:06:43 UTC (854 KB)